Pneumocystis Carinii Pneumonia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
[Report Updated: 30-05-2017]

Published by Delve Insight: 30 May 2017 | 86542
Related Topics: Pneumonia

Sorry, this report is no longer available.

We may have other suitable reports available - try Searching for Pneumocystis
or contact our sales team for personal assistance: phone +44 (0)7887945155 or email pdb@bioportfolio.co.uk.

Introduction

DelveInsight’s Report, “Pneumocystis Carinii Pneumonia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Pneumocystis Carinii Pneumonia Report is to understand the market and pipeline status of the drugs around the Pneumocystis Carinii Pneumonia to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Pneumocystis Carinii Pneumonia. While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 48-72 Hours to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE:

• A snapshot of the global Market and Phase III therapeutics scenario for Pneumocystis Carinii Pneumonia.

• A review of the marketed products under prescription for Pneumocystis Carinii Pneumonia, regulatory information and marketing status.

• Coverage of global patent coverage and detailed commentaries on the US patent challenges.

• Graphical representation of investigational products for patent expiry and market exclusivities across the globe.

• Product profiles for marketed products for Pneumocystis Carinii Pneumonia with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.

• Coverage of API Manufacturers for Pneumocystis Carinii Pneumonia drugs in the United States, Europe and Asian Regions with location details.

• Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Pneumocystis Carinii Pneumonia drugs.

• Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Pneumocystis Carinii Pneumonia drugs.

• Coverage of Pneumocystis Carinii Pneumonia Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.

• Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.

• Key discontinued Marketed products.

• Global Sales Figure to 2018.

Reasons to buy

• Evaluate the marketing status and exclusivity details of Pneumocystis Carinii Pneumonia key products to exploit opportunities for generic drug development opportunities.

• Identify and understand important and diverse types of therapeutics under Phase III development for Pneumocystis Carinii Pneumonia.

• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Pneumocystis Carinii Pneumonia.

• API intelligence over marketed drugs forPneumocystis Carinii Pneumoniaand gaining primary intelligence over active ingredients manufacturers across the globe.

• API intelligence over leading Phase III Pipeline drugs.

• Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.

• Understanding the scope of the Phase III Drugs with nil regulatory filings.

• Understanding the chemical route of synthesis of approved drugs for Pneumocystis Carinii Pneumonia.

• Uncovering opportunities in the rapidly growing US market.

Table of Contents
for Pneumocystis Carinii Pneumonia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 [Report Updated: 30-05-2017]

List Of Tables
in Pneumocystis Carinii Pneumonia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 [Report Updated: 30-05-2017]

• Pneumocystis Carinii Pneumonia Therapeutic Market, US, Marketed Drugs by Application Type, 2017

• Pneumocystis Carinii Pneumonia Therapeutic Market, US, Marketed Drugs by Marketing Status, 2017

• Pneumocystis Carinii Pneumonia Therapeutic Market, US, (Year), 2017

• Pneumocystis Carinii Pneumonia Marketed Drugs, API Manufacturers by US DMF Status, 2017

• Pneumocystis Carinii Pneumonia Marketed Drugs, US DMF Status Drug Specific (Number), 2017

• Pneumocystis Carinii Pneumonia Drugs, API Manufacturers, Europe by Country, 2017

• Pneumocystis Carinii Pneumonia Drugs, API Manufacturers, India by State, 2017

• Pneumocystis Carinii Pneumonia Drugs, API Manufacturers, China by Province, 2017

• Pneumocystis Carinii Pneumonia Drugs, API Manufacturers by Geography 2017

• Pneumocystis Carinii Pneumonia Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017

• Pneumocystis Carinii Pneumonia Therapeutic Market, Global Sales-2018 (in million USD)

• API Manufacturers for Drug, 2017

• Phase III Drugs for Pneumocystis Carinii Pneumonia, 2017

• Discontinued Drugs for Pneumocystis Carinii Pneumonia, 2017

List Of Figures, Charts and Diagrams
in Pneumocystis Carinii Pneumonia-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 [Report Updated: 30-05-2017]

• Pneumocystis Carinii Pneumonia Therapeutic Market, US, Marketed Drugs by Application Type (%), 2017

• Pneumocystis Carinii Pneumonia Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2017

• Pneumocystis Carinii Pneumonia Therapeutic Market, US, (Year), 2017

• Pneumocystis Carinii Pneumonia Marketed Drugs, API Manufacturers by US DMF Status (%), 2017

• Pneumocystis Carinii Pneumonia Marketed Drugs, US DMF Status Drug Specific (Number), 2017

• Pneumocystis Carinii Pneumonia Drugs, API Manufacturers, Europe by Country, 2017

• Pneumocystis Carinii Pneumonia Drugs, API Manufacturers, India by State, 2017

• Pneumocystis Carinii Pneumonia Drugs, API Manufacturers, China by Province, 2017

• Pneumocystis Carinii Pneumonia Drugs, API Manufacturers by Geography 2017

• Pneumocystis Carinii Pneumonia Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017

• Pneumocystis Carinii Pneumonia Therapeutic Market, Global Sales 2018 (in million USD)

• Drug, Patent/Exclusivity Expiry (Year), 2017

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

86542 | DIIR2017376

Number of Pages

100

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Pneumocystis pneumonia- Market Insights, Epidemiology and Market Forecast 2028
Report Summary"Pneumocystis pneumonia- Market Insights, Epidemiology and Market Forecast 2028" repor...
26 Jul 2019 by MIReports USD $5,980 More Info
2019 Pneumocystis carinii Pneumonia Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025
The global clinical trial report- “2019 Pneumocystis carinii Pneumonia Clinical Trials Study” provid...
24 Apr 2019 by VPA Research USD $1,799 More Info
Pneumocystis carinii Pneumonia Global Clinical Trials Review, H1, 2018
Pneumocystis carinii Pneumonia Global Clinical Trials Review, H1, 2018SummaryGlobalData's clinical t...
28 May 2018 by Global Data USD $2,500 More Info
Pneumocystis Carinii Pneumonia-Pipeline Insights, 2017
DelveInsight’s, “ Pneumocystis Carinii Pneumonia-Pipeline Insights, 2017”, report provides in depth ...
30 May 2017 by Delve Insight USD $1,250 More Info
Pneumocystis Infection-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
DelveInsight’s Report, “Pneumocystis Infection-Global API Manufacturers, Marketed and Phase III Drug...
30 May 2017 by Delve Insight USD $2,000 More Info
Pneumocystis carinii Pneumonia Global Clinical Trials Review, H2, 2016
Pneumocystis carinii Pneumonia Global Clinical Trials Review, H2, 2016SummaryGlobalData's clinical t...
30 Sep 2016 by Global Data USD $2,500 More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

We Stock...